Keyphrases
Monotherapy
100%
Immune Checkpoint Inhibitors
100%
Pre-existing Autoimmune Disease
100%
Immune-related Adverse Events
50%
Immune Checkpoint Inhibitor Combinations
50%
Progression-free Survival
33%
Cumulative Incidence
33%
Disease Flare
33%
Subdistribution Hazard Ratio
33%
Cancer Patients
16%
Overall Survival
16%
In Cancer
16%
Lung Cancer
16%
Treatment-related Mortality
16%
Melanoma
16%
Toxicity Profile
16%
Clinical Trials
16%
Cancer Therapy
16%
Inhibitor Agent
16%
Melanoma Progression
16%
Retrospective Observational Study
16%
Immune Checkpoint Inhibitor Therapy
16%
Immune Checkpoint Inhibitor Toxicity
16%
Immune Checkpoint Inhibitor Combination Therapy
16%
Medicine and Dentistry
Autoimmune Disease
100%
Monotherapy
100%
Immune Checkpoint Inhibitor
100%
Immune-Related Adverse Events
27%
Hazard Ratio
18%
Melanoma
18%
Progression Free Survival
18%
Disease Exacerbation
18%
Cumulative Incidence
18%
Malignant Neoplasm
9%
Combination Therapy
9%
Clinical Trial
9%
Overall Survival
9%
Lung Cancer
9%
Cancer Therapy
9%
Observational Study
9%
Dermatological Agent
9%
Pharmacology, Toxicology and Pharmaceutical Science
Autoimmune Disease
100%
Monotherapy
100%
Immune Checkpoint Inhibitor
100%
Malignant Neoplasm
27%
Adverse Event
27%
Melanoma
18%
Progression Free Survival
18%
Disease Exacerbation
18%
Overall Survival
9%
Clinical Trial
9%
Combination Therapy
9%
Lung Cancer
9%
Observational Study
9%
Dermatological Agent
9%
Immunology and Microbiology
Immunity
100%
Autoimmune Disease
100%
Progression Free Survival
14%
Overall Survival
7%